3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Brain Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Polycythemia Vera
4
Glioblastoma
4
Meningioma
3
Leukemia, Myeloid, Acute
3
Pharyngeal Neoplasms
2
Paranasal Sinus Neoplasms
2
Neoplasms
2
Laryngeal Neoplasms
2
Head and Neck Neoplasms
2
Gliosarcoma
2
Thrombocytosis
1
Thrombocythemia, Essential
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Papillomavirus Infections
1
Oropharyngeal Neoplasms
1
Nose Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Hodgkin Disease
1
Glioma
1
Epstein-Barr Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Astrocytoma
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
130
Methotrexate
93
fludarabine phosphate
74
Cytarabine
71
Vincristine
66
Whole-Body Irradiation
65
Mycophenolic Acid
58
Dexamethasone
55
Tacrolimus
49
Peripheral Blood Stem Cell Transplantation
48
fludarabine
47
Busulfan
46
pegaspargase
43
Filgrastim
41
Etoposide
41
Doxorubicin
41
Calcium Dobesilate
40
Granulocyte Colony-Stimulating Factor
39
Rituximab
36
Cyclosporine
36
Mercaptopurine
35
Melphalan
33
Prednisone
31
merphos
28
Clofarabine
26
Asparaginase
26
Antilymphocyte Serum
25
Leucovorin
23
Daunorubicin
23
Thiotepa
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Hydroxyurea
×
Clear all
NCT03860844
2025-09-09
ISAKIDS
Sanofi
Phase 2
Terminated
67 enrolled
25 charts